Subcutaneous VIS649, an APRIL-Neutralizing Antibody: Preliminary Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of VIS649-102, a Phase 1, Single Ascending Dose Study in Healthy Volunteers
Xiaoyan Zhang(Fujian Medical University), Susan Sloan(Visterra (United States)), Asher D. Schachter(Visterra (United States)), Yanlin Wang(Luliang University), Jill Yarbrough(Visterra (United States))
Cited by 0
Related Papers
Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential
|The Journal of Experimental Medicine|2003|897
Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible
|Nature Genetics|2006|567
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection
|Proceedings of the National Academy of Sciences|2013|287
Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells
|Nature Communications|2015|276